Page 66 - 2021_06-Haematologica-web

S. Chiaretti et al.
Engl J Med. 2014;371(11):1005-1015.
5. Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lym- phoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394-401.
6. Herold T, Schneider S, Metzeler KH, et al. Adults with philadelphia chromosome–like acute lymphoblastic leukemia frequently have igh-CRLF2 and JAK2 mutations, per- sistence of minimal residual disease and poor prognosis. Haematologica. 2017; 102(1):130-138.
7. Chiaretti S, Messina M, Grammatico S, et al. Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quanti- tative real time-polymerase chain reaction: clinical, prognostic and therapeutic implica- tions. Br J Haematol. 2018;181(5):642-652.
8.Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lym- phoblastic leukemia. Blood. 2012; 120(17):3510-3518.
9.Lengline E, Beldjord K, Dombret H, et al. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lym- phoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013;98(11):146-148.
10. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1- PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013;31(25):e413- 416.
11.Fazio F, Barberi W, Cazzaniga G, et al. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with EBF1- PDGFRB fusion transcript. Leuk Lymphoma. 2020;61(2):469-472.
12. Tasian SK, Teachey DT, Li Y, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft mod- els of Ph-like acute lymphoblastic leukemia. Blood. 2017;129(2):177-187.
13.Harvey RC, Kang H, Roberts KG, et al. Development and validation of a highly sen- sitive and specific gene expression classifier to prospectively screen and identify B-pre-
cursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome- like (“Ph-like” or “BCR-ABL1-Like”) signa- ture for therapeutic targeting and clinical intervention. Blood. 2013;122(21):826.
14. Heatley SL, Sadras T, Kok CH, et al. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica. 2017;102(12):e490-e493.
15. Roberts KG. The biology of Philadelphia chromosome-like ALL. Best Pract Res Clin Haematol. 2017;30(3):212-221.
16.Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32(27):3012-3020.
17. Stock W, Luger SM, Advani AS, et al. A pedi- atric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559.
18.Tasian SK, Hurtz C, Wertheim GB, et al. High incidence of Philadelphia chromo- some-like acute lymphoblastic leukemia in older adults with B-ALL. Leukemia. 2017; 31(4):981-984.
19. Jain N, Roberts KG, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129(5):572- 581.
20. Bassan R, Chiaretti S, Paoloni F, et al. First results of the GIMEMA LAL1913 protocol for adult patients with Philadelphia-negative acute lymphoblastic leukemia (Ph- ALL). On behalf of the GIMEMA Acute Leukemia Working Group. PS919. HemaSphere. 2018;2(S1):408.
21.Messina M, Chiaretti S, Wang J, et al. Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. Oncotarget. 2016;7(12):13886-13901.
21. Messina M, Chiaretti S, Fedullo AL, et al. Clinical significance of recurrent copy num- ber aberrations in B-lineage acute lym- phoblastic leukaemia without recurrent fusion genes across age cohorts. Br J Haematol. 2017;178(4):583-587.
23. Fedullo AL, Messina M, Elia L, et al. Prognostic implications of additional genomic lesions in adult Ph+ acute lym- phoblastic leukemia. Haematologica. 2019; 104(2):312-318.
24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap). A metadata-driven methodology and workflow process for pro- viding translational research informatics sup- port. J Biomed Inform. 2009;42(2):377-381.
25. Chiaretti S, Brugnoletti F, Messina M, et al. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell pre- cursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leuk Res. 2016;41:36-42.
26.Russell LJ, Jones L, Enshaei A, et al. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2017;56(5):363-372.
27. Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high-risk B-ALL: A study from the Children’s Oncology Group. Blood. 2017;129(25):3352- 3361.
28. Roberts KG, Reshmi SC, Harvey RC, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the children’s oncology group. Blood. 2018;132(8):815-824.
29. Chiaretti S, Taherinasab A, Canichella M, et al. The Validation of the BCR/ABL1-like pre- dictor across laboratories shows repro- ducibility of results. Blood. 2019: 134 (Suppl 1):S5211.
30. Chiaretti S, Messina M, Foà R. BCR/ABL1- like acute lymphoblastic leukemia: how to diagnose and treat? Cancer. 2019;125(2): 194-204.
31. Tanasi I, Ba I, Sirvent N, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL- class rearrangements. Blood. 2019;134(16): 1351-1355.
32. Foà R, Bassan R, Vitale A, et al. GIMEMA Investigators. Dasatinib-nlinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613- 1623.
1568
haematologica | 2021; 106(6)